Inserm U1148, Department of Cardiology, hôpital Bichat, AP-HP, 6, rue Henri-Huchard, 75018 Paris, France.
Department of Cardiology, Paris-Descartes University, hôpital Européen Georges-Pompidou, AP-HP, 75015 Paris, France.
Arch Cardiovasc Dis. 2019 Apr;112(4):241-252. doi: 10.1016/j.acvd.2018.11.003. Epub 2019 Jan 11.
Cardiovascular disease (CVD) is a major cause of death worldwide, and fruitful research is needed for future advances in this field.
To analyse the scientific production and vitality of French cardiovascular clinical research, and its evolution over the last decade.
We first used Lab Times online data obtained through the Web of Science (Thomson-Reuters, Toronto, ON, Canada), then the PubMed database (National Center for Biotechnology Information [NCBI], Bethesda, MD, USA), for studies published between 2005 and 2015 in the multidisciplinary and cardiology journals with the highest impact factors. French abstracts submitted and accepted at the European Society of Cardiology (ESC) congress were provided directly by the ESC. The number of cardiovascular projects was analysed through the http://www.ClinicalTrials.gov database and the French site for government-funded projects, over the decade from 2008 to 2017.
Overall, France was ranked fifth in Europe and eighth worldwide for CVD publications. During the 10-year period from 2005 to 2015, French publications accounted for 0.2-0.3% of articles in top multidisciplinary journals and 2% of articles in top cardiology journals. We observed a steady decrease in French abstract submissions at the ESC congress (from 5% to 3.5% in 10 years), and in 2017, France was ranked eighth in Europe. Across European countries, France has been ranked first for declared cardiovascular research on http://www.ClinicalTrials.gov over the last 3 years, for both interventional and observational studies. Regarding the Hospital Programme of Clinical Research, heart ranked second after neurosciences.
France is very well represented in terms of new CVD projects, but actual French scientific production scores poorly. Investing in CVD research is a priority to increase the level of publication and to compete with other leading countries.
心血管疾病（CVD）是全球范围内主要的死亡原因，因此在该领域需要进行富有成果的研究以取得未来的进展。
分析法国心血管临床研究的科学产出和活力及其在过去十年中的演变。
我们首先使用在线 Lab Times 数据（由 Thomson-Reuters，多伦多，ON，加拿大）从 Web of Science 中获得，然后使用 PubMed 数据库（美国国立生物技术信息中心 [NCBI]，贝塞斯达，MD），对 2005 年至 2015 年期间发表在具有最高影响因子的多学科和心脏病学期刊上的研究进行分析。欧洲心脏病学会（ESC）大会上提交和接受的法国摘要直接由 ESC 提供。通过 http://www.ClinicalTrials.gov 数据库和 2008 年至 2017 年十年间法国政府资助项目的网站分析心血管项目的数量。
总体而言，法国在 CVD 出版物方面在欧洲排名第五，在全球排名第八。在 2005 年至 2015 年的十年期间，法国的出版物在顶级多学科期刊中占 0.2-0.3%的文章，在顶级心脏病学期刊中占 2%的文章。我们观察到 ESC 大会上法国摘要提交的数量稳步下降（在 10 年内从 5%降至 3.5%），而在 2017 年，法国在欧洲排名第八。在欧洲各国中，法国在过去三年中在 http://www.ClinicalTrials.gov 上宣布的心血管研究方面排名第一，无论是干预性研究还是观察性研究。在医院临床研究计划中，心脏病学仅次于神经科学排名第二。
法国在新的 CVD 项目方面表现出色，但实际的法国科学产出得分较低。投资于 CVD 研究是提高出版水平并与其他领先国家竞争的优先事项。
